ArticleBMC public health2025
Impact of national reimbursement policy supporting test strips on glycemic control in people with insulin-treated diabetes: retrospective cohort study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelf-monitoring blood glucose (SMBG) is an important factor for glycemic control in people with diabetes. Many countries have implemented policies to support SMBG for better glycemic control. The long-term impact of supporting the cost of SMBG strips for glycemic control in type 1 diabetes mellitus (T1DM) and insulin-treated type 2 DM (T2DM) have been determined in only a few studies.
methodsPeople with T1DM and insulin-treated T2DM for whom the cost of blood glucose strips was and was not supported were included in the present study. Longitudinal changes in HbA1c were repeatedly measured in people with T1DM and insulin-treated T2DM at baseline, and 3, 6, 9, and 12 months. The inverse probability of treatment weighting (IPTW) linear mixed effect model (LMM) analysis was used.
resultsAmong people with T1DM and insulin-treated T2DM, subjects who received support for strip prescriptions showed significantly decreased hemoglobin A1c (HbA1c) levels (0.78% and 0.92% at 12 months, respectively), with significant between-group differences compared with subjects who did not receive support (p < 0.001). When using the IPTW-LMM after adjusting for covariates, the mean reduction in HbA1c every 3 months in T1DM and insulin-treated T2DM subjects with strip prescriptions was - 0.105% (95% CI: -0.197 to - 0.014) and - 0.112% (95% CI: -0.143 to - 0.082), respectively, compared with their respective control groups without strip prescriptions.
conclusionsIn conclusion, the reimbursement policy supporting the cost of blood glucose strip prescriptions was associated with significant reduction in HbA1c levels in people with T1DM or insulin-treated T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.